A Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RPT1G After Single and Multiple Doses in Healthy Adult Participants
Latest Information Update: 26 May 2025
At a glance
- Drugs RPT 1G (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Remedy Plan Therapeutics
Most Recent Events
- 18 May 2025 Planned End Date changed from 15 May 2025 to 2 Jul 2025.
- 18 May 2025 Planned primary completion date changed from 15 Apr 2025 to 1 Jul 2025.
- 18 May 2025 Status changed from recruiting to active, no longer recruiting.